English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Press Releases for Friday, February 14, 2020
Blue Orca's Short Selling Plan Failed Because the Quality China Medical System (867.HK) Can Withstand Severe Tests 
18:00 HKT/SGT
China Medical System (867.HK) Armed against Short Selling! The Biggest CSO Took Control of Full Industrial Chain 
17:25 HKT/SGT
《大富翁10》首次使用粤语配音,上线后蝉联当月国产单机销量第一  
17:03 HKT/SGT
《大富翁10》首次使用粵語配音,上線後蟬聯當月國產單機銷量第一 
17:02 HKT/SGT
五龍電動車“內鬥”背後 大股東曾提零傭金包銷供股方案  
16:14 HKT/SGT
MHI: Charter of Trust Partners Decide on Further Measures for More Cybersecurity 
15:52 HKT/SGT
华领医药任命前美国FDA官员汤福兴博士为首席技术官 
15:23 HKT/SGT
華領醫藥任命前美國FDA官員湯福興博士為首席技術官 
15:22 HKT/SGT
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer 
15:21 HKT/SGT
エーザイ、人事異動(2020年2月14日付)を発表 
15:00 HKT/SGT
JumpStart, Subsidiary of NetDragon, Collaborates with Beach House Pictures To Develop First-Ever Neopets Animated TV Series 
14:28 HKT/SGT
神奈川県道路公社、日立などと共同で「ワンストップ型ETC」導入に向けた社会実験を実施 有料道路で国内初 
14:00 HKT/SGT
KDDI・大林組・NEC、5Gで掘削・運搬・転圧など一連の道路造成工事の実証に成功 
13:00 HKT/SGT
Honda、新型軽二輪スクーター「ADV150」の受注状況について 
11:30 HKT/SGT
Honda、マットカラーを採用した「PCX」と「PCX150」を受注期間限定で発売 
11:30 HKT/SGT
网龙子公司JumpStart与Beach House Pictures携手开发首部Neopets动画系列 
11:27 HKT/SGT
網龍子公司JumpStart與Beach House Pictures攜手開發首部Neopets動畫系列 
11:26 HKT/SGT
JumpStart, Subsidiary of NetDragon, Collaborates with Beach House Pictures To Develop First-Ever Neopets Animated TV Series 
11:25 HKT/SGT
TOYOTA、GRスープラ(3.0L)のエンジン改良型を発表 
09:00 HKT/SGT
韩国加密货币交易所APRObit采用Bitfinex联合订单系统,于3月启动 
08:39 HKT/SGT
韓國加密貨幣交易所APRObit採用Bitfinex聯合訂單系統,於3月上線 
08:38 HKT/SGT
South Korean Crypto Exchange APRObit Adopts Bitfinex Joint Order Book System, Launching in March 
08:37 HKT/SGT
PT Hutama Karya exceeds forecasts, reports 43% increase in profits 
01:00 HKT/SGT
 ACN Search:
 
Eesee Implements Blockpass for Compliance in Digital Assets Marketplace
 
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575